Nurix Therapeutics, Inc. Financials
Nurix Therapeutics, Inc. (NRIX) reported $36.8M in revenue over the twelve months to May 31, 2026, down 58.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External capital, not revenue, is funding operations as R&D spending scales far faster than the top line.
By FY2025, operating cash burn had reached-$249.5M even though revenue was only$84.0M , showing that commercial inflows are still small relative to the research engine. Liquidity looked stronger at the same time because cash climbed to$247.0M and FY2024-FY2025 financing inflows totaled$724.3M , so the sturdier balance sheet reflects external funding more than operating self-sufficiency.
In FY2025, free cash flow of
Current assets of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nurix Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nurix Therapeutics, Inc. scores 8.54, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.7B) relative to total liabilities ($149.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nurix Therapeutics, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Nurix Therapeutics, Inc. reported a net loss of $264.5M while operations used $249.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Nurix Therapeutics, Inc. generated $84.0M in revenue in fiscal year 2025. This represents an increase of 54.0% from the prior year.
Nurix Therapeutics, Inc.'s EBITDA was -$276.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.9% from the prior year.
Nurix Therapeutics, Inc. reported -$264.5M in net income in fiscal year 2025. This represents a decrease of 36.6% from the prior year.
Nurix Therapeutics, Inc. earned -$3.05 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 5.9% from the prior year.
Cash & Balance Sheet
Nurix Therapeutics, Inc. recorded an outflow of $263.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 44.9% from the prior year.
Nurix Therapeutics, Inc. held $247.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Nurix Therapeutics, Inc. paid $0.00 per share in dividends in fiscal year 2025.
Margins & Returns
Nurix Therapeutics, Inc.'s ROE was -49.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Nurix Therapeutics, Inc. invested $316.9M in research and development in fiscal year 2025. This represents an increase of 43.0% from the prior year.
Nurix Therapeutics, Inc. invested $14.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 51.0% from the prior year.
Not reported for fiscal year 2025.
NRIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M+44.6% | $6.3M-54.0% | $13.6M+72.0% | $7.9M-82.1% | $44.1M+138.7% | $18.5M+38.9% | $13.3M+5.5% | $12.6M |
| R&D Expenses | $87.7M+4.2% | $84.1M+1.3% | $83.0M-3.6% | $86.1M+10.3% | $78.1M+12.1% | $69.7M+3.6% | $67.2M+21.2% | $55.5M |
| SG&A Expenses | $15.6M+6.7% | $14.6M+7.0% | $13.6M+3.7% | $13.2M-7.9% | $14.3M+22.6% | $11.7M+8.7% | $10.7M-8.5% | $11.7M |
| Operating Income | -$94.2M-1.8% | -$92.5M-11.3% | -$83.1M+9.1% | -$91.4M-89.1% | -$48.3M+23.1% | -$62.9M+2.8% | -$64.7M-18.4% | -$54.6M |
| Income Tax | -$271K | $0 | $0 | $0-100.0% | $760K | $0-100.0% | $8K-90.2% | $82K |
| Net Income | -$89.5M-2.7% | -$87.2M-11.4% | -$78.2M+9.5% | -$86.4M-98.8% | -$43.5M+22.9% | -$56.4M+3.8% | -$58.5M-19.6% | -$49.0M |
| EPS (Diluted) | -$0.81-2.5% | -$0.79+4.8% | -$0.83+19.4% | -$1.03-98.1% | -$0.52+22.4% | -$0.67+10.7% | -$0.75-11.9% | -$0.67 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
NRIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $535.5M-15.8% | $636.1M-7.6% | $688.1M+31.7% | $522.5M-11.7% | $591.6M-3.8% | $615.0M-8.1% | $669.3M+30.3% | $513.6M |
| Current Assets | $456.5M-17.7% | $554.4M-8.6% | $606.8M+37.7% | $440.6M-14.5% | $515.3M-8.6% | $563.7M-9.0% | $619.4M+35.8% | $456.0M |
| Cash & Equivalents | $67.7M-4.9% | $71.2M-71.2% | $247.0M+214.8% | $78.4M-6.9% | $84.3M+11.0% | $75.9M-31.0% | $110.0M+11.1% | $99.0M |
| Accounts Receivable | N/A | N/A | N/A | N/A | $19.0M | N/A | $0 | N/A |
| Total Liabilities | $132.9M-14.4% | $155.2M+3.9% | $149.4M-0.6% | $150.2M+4.4% | $144.0M+7.3% | $134.1M-5.8% | $142.3M+4.1% | $136.7M |
| Current Liabilities | $72.0M-21.9% | $92.2M+6.6% | $86.5M+5.0% | $82.3M+8.9% | $75.6M-16.0% | $90.0M-6.1% | $95.9M+11.1% | $86.3M |
| Total Equity | $402.6M-16.3% | $480.9M-10.7% | $538.7M+44.7% | $372.3M-16.8% | $447.6M-6.9% | $480.9M-8.7% | $527.0M+39.8% | $376.9M |
| Retained Earnings | -$1.2B-8.2% | -$1.1B-8.7% | -$1.0B-8.5% | -$925.0M-10.3% | -$838.6M-5.5% | -$795.1M-7.6% | -$738.8M-8.6% | -$680.2M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
NRIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$96.6M-34.3% | -$71.9M-6.0% | -$67.8M-18.2% | -$57.4M+9.1% | -$63.2M-3.4% | -$61.1M-25.3% | -$48.8M-15.6% | -$42.2M |
| Capital Expenditures | $1.9M+85.3% | $1.0M-79.6% | $5.1M+89.3% | $2.7M+1.3% | $2.7M-23.2% | $3.5M+65.6% | $2.1M-10.3% | $2.3M |
| Free Cash Flow | -$98.5M-35.0% | -$73.0M0.0% | -$73.0M-21.4% | -$60.1M+8.7% | -$65.8M-2.0% | -$64.6M-27.0% | -$50.9M-14.2% | -$44.5M |
| Investing Cash Flow | $93.0M+175.1% | -$123.8M-35887.9% | $346K-99.3% | $50.5M-29.4% | $71.5M+180.0% | $25.5M+118.1% | -$140.8M-559.9% | -$21.3M |
| Financing Cash Flow | $66K-99.7% | $20.0M-91.5% | $236.0M+20333.6% | $1.2M+19150.0% | $6K-99.6% | $1.5M-99.3% | $200.5M+338.1% | $45.8M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NRIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1041.7% | -1479.4% | -612.0% | -1157.6% | -109.7% | -340.7% | -486.7% | -433.8% |
| Net Margin | -990.1% | -1394.3% | -576.1% | -1094.8% | -98.7% | -305.4% | -440.8% | -388.9% |
| Return on Equity | -22.2%-4.1pp | -18.1%-3.6pp | -14.5%+8.7pp | -23.2%-13.5pp | -9.7%+2.0pp | -11.7%-0.6pp | -11.1%+1.9pp | -13.0% |
| Return on Assets | -16.7%-3.0pp | -13.7%-2.3pp | -11.4%+5.2pp | -16.5%-9.2pp | -7.3%+1.8pp | -9.2%-0.4pp | -8.8%+0.8pp | -9.5% |
| Current Ratio | 6.34+0.3x | 6.01-1.0x | 7.02+1.7x | 5.35-1.5x | 6.82+0.6x | 6.26-0.2x | 6.46+1.2x | 5.28 |
| Debt-to-Equity | 0.330.0x | 0.320.0x | 0.28-0.1x | 0.40+0.1x | 0.320.0x | 0.280.0x | 0.27-0.1x | 0.36 |
| FCF Margin | -1089.3% | -1167.0% | -537.4% | -761.3% | -149.4% | -349.9% | -382.8% | -353.7% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Nurix Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Nurix Therapeutics, Inc.'s annual revenue?
Nurix Therapeutics, Inc. (NRIX) reported $84.0M in total revenue for fiscal year 2025. This represents a 54.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nurix Therapeutics, Inc.'s revenue growing?
Nurix Therapeutics, Inc. (NRIX) revenue grew by 54.0% year-over-year, from $54.5M to $84.0M in fiscal year 2025.
Is Nurix Therapeutics, Inc. profitable?
No, Nurix Therapeutics, Inc. (NRIX) reported a net income of -$264.5M in fiscal year 2025.
What is Nurix Therapeutics, Inc.'s EBITDA?
Nurix Therapeutics, Inc. (NRIX) had EBITDA of -$276.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nurix Therapeutics, Inc.'s return on equity (ROE)?
Nurix Therapeutics, Inc. (NRIX) has a return on equity of -49.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nurix Therapeutics, Inc.'s free cash flow?
Nurix Therapeutics, Inc. (NRIX) recorded an outflow of $263.5M in free cash flow during fiscal year 2025. This represents a -44.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nurix Therapeutics, Inc.'s operating cash flow?
Nurix Therapeutics, Inc. (NRIX) recorded an outflow of $249.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nurix Therapeutics, Inc.'s total assets?
Nurix Therapeutics, Inc. (NRIX) had $688.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nurix Therapeutics, Inc.'s capital expenditures?
Nurix Therapeutics, Inc. (NRIX) invested $14.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nurix Therapeutics, Inc. spend on research and development?
Nurix Therapeutics, Inc. (NRIX) invested $316.9M in research and development during fiscal year 2025.
What is Nurix Therapeutics, Inc.'s current ratio?
Nurix Therapeutics, Inc. (NRIX) had a current ratio of 7.02 as of fiscal year 2025, which is generally considered healthy.
What is Nurix Therapeutics, Inc.'s debt-to-equity ratio?
Nurix Therapeutics, Inc. (NRIX) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nurix Therapeutics, Inc.'s return on assets (ROA)?
Nurix Therapeutics, Inc. (NRIX) had a return on assets of -38.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Nurix Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Nurix Therapeutics, Inc. (NRIX) held $592.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $249.5M over that year. Dividing the one by the other, the reported balance equals about 29 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Nurix Therapeutics, Inc.'s Altman Z-Score?
Nurix Therapeutics, Inc. (NRIX) has an Altman Z-Score of 8.54, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nurix Therapeutics, Inc.'s Piotroski F-Score?
Nurix Therapeutics, Inc. (NRIX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nurix Therapeutics, Inc.'s earnings high quality?
Nurix Therapeutics, Inc. (NRIX) reported a net loss of $264.5M while operations used $249.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Nurix Therapeutics, Inc.?
Nurix Therapeutics, Inc. (NRIX) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.